Surekha Collur, MD
Ophthalmology · Holmdel, NJNPI 1750491015
Payments from drug & device makers
Across 251 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$597
- Alcon$578
- Bausch & Lomb Americas Inc.$446
- Glaukos Corporation$318
- Biotissue Holdings Inc.$251
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,84998%
- Education$250%
- Gifts$621%
- Other$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 81 | $1,714 |
| Sun Pharmaceutical Industries Inc. | 33 | $597 |
| Alcon | 22 | $578 |
| Bausch & Lomb Americas Inc. | 20 | $446 |
| Glaukos Corporation | 5 | $318 |
| Biotissue Holdings Inc. | 9 | $251 |
| Nova Eye, Inc. | 1 | $234 |
| Sight Sciences, Inc. | 6 | $188 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $170 |
| Oyster Point Pharma, Inc. | 10 | $165 |
| Amgen(2 entities) | 2 | $144 |
| Rxsight Inc | 2 | $132 |
| Novartis | 9 | $120 |
| Apellis Pharmaceuticals, Inc. | 1 | $115 |
| Kala Pharmaceuticals, Inc. | 7 | $107 |
| Aerie Pharmaceuticals, Inc. | 7 | $99 |
| Dompe US, Inc. | 5 | $86 |
| Harrow Eye, LLC | 4 | $67 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $55 |
| Carl Zeiss Meditec, Inc. | 2 | $53 |
| Thea Pharma Inc. | 3 | $51 |
| NEW World Medical,inc. | 2 | $46 |
| Eyevance Pharmaceuticals LLC | 3 | $46 |
| Coopervision Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 2 | $35 |
| Eyepoint US, Inc. | 2 | $29 |
| Quidel Corporation | 1 | $26 |
| Beaver-visitec International, Inc. | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$248
- DURYSTA$244
- enVista MX60 IOL$156
- Rocklatan$138
- Rhopressa$138
- RESTASIS MULTIDOSE$128
- CEQUA$125
- TEPEZZA$125
- CATALYS SYSTEM$124
- XEN GLAUCOMA TREATMENT SYSTEM$123
- RXSIGHT CONTACT LENS$113
- RXSIGHT INJECTOR CARTRIDGE$113
- RXSIGHT INJECTOR HANDPIECE$113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
- Prokera$109
- AmnioGraft$109
- VUITY$100
How this compares
$5,963 in reported general payments places this provider in the 85th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 108 | $135,124 |
| XiidraLifitegrast | 84 | $112,195 |
| Cyclosporine | 60 | $48,638 |
| LumiganBimatoprost | 69 | $37,285 |
| RocklatanNetarsudil Mesylat/Latanoprost | 54 | $35,832 |
| RhopressaNetarsudil Mesylate | 47 | $27,753 |
| VyzultaLatanoprostene Bunod | 51 | $21,085 |
| CequaCyclosporine | 17 | $19,763 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 36 | $12,152 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $10,846 |
| Alphagan PBrimonidine Tartrate | 24 | $10,219 |
| MieboPerfluorohexyloctane/Pf | 11 | $10,038 |
| TafluprostTafluprost/Pf | 24 | $8,932 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $8,755 |
| Prednisolone Acetate | 226 | $8,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $1,714 | $191,383226 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $446 | $143,318146 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $99 | $63,585101 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $597 | $19,76317 claims |
| AlconSimbrinza | $578 | $10,84639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Holmdel
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.